Blog

Steps to eliminating vaccine-preventable cancers taken by The Council of the European Union – European Cancer Organisation

Photo taken from European Cancer Organisation/LinkedIn

Jun 24, 2024, 14:05

Steps to eliminating vaccine-preventable cancers taken by The Council of the European Union – European Cancer Organisation

European Cancer Organisation shared a post on LinkedIn: .

“The Council of the European Union is taking significant steps to eliminating vaccine-preventable cancers

New recommendations have been adopted at the EPSCO – Employment, Social Policy, Health and Consumer Affairs Council meeting today. Here are the key highlights:

Introducing 19 measures to boost HPV and HepB vaccination uptake by removing structural barriers for disadvantaged and high-risk groups
Expanding access to vaccination by providing the service free of charge or fully reimbursable
Enhancing data-driven decision-making for vaccination programmes
Ensuring the European Centre for Disease Prevention and Control will display national data on HPV coverage rates in EU member states on a dedicated dashboard by the end of the year
Promoting a target for the percentage of boys to be vaccinated against HPV by 2030.
Focusing on high-risk groups for HepB and reaching the 2030 goal of hepatitis elimination through 95% vaccination coverage.

Read the full recommendations here.

We are eager to help member states implement these actions. Together, we can achieve a world where vaccine-preventable cancers are a thing of the past.”

Source: European Cancer Organisation/LinkedIn

2030 goals cancer Cancer Prevention Council of the European Union data-driven decision-making disadvantaged groups EPSCO European Cancer Organisation European Centre for Disease Prevention and Control health policy healthcare advocacy healthcare recommendations hepatitis elimination HepB vaccination high-risk groups HPV coverage rates HPV Vaccination OncoDaily Oncology public health vaccination accessibility vaccination target vaccination uptake Vaccine-Preventable Cancers

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Special Coverage